Investigation into Gossamer Bio's Trial Results and Prior Statements to Investors

Gossamer Bio's Phase 3 PROSERA study of seralutinib missed its primary endpoint in pulmonary arterial hypertension. CEO Faheem Hasnain expressed optimism about trial results in May 2025, but the study's p-value of 0.032 failed to meet the prespecified significance threshold of 0.025. Levi & Korsinsky, LLP is investigating whether prior statements to investors were accurate when made. Shareholders who purchased GOSS and suffered a loss are encouraged to submit their information.